1st Edition
by Steven Gray (Editor)
Epigenetic Cancer Therapy
unites issues central to a translational audience actively seeking to
understand the topic. It is ideal for cancer specialists, including
oncologists and clinicians, but also provides valuable information for
researchers, academics, students, governments, and decision-makers in
the healthcare sector.
The text covers the basic background of
the epigenome, aberrant epigenetics, and its potential as a target for
cancer therapy, and includes individual chapters on the state of
epigenome knowledge in specific cancers (including lung, breast,
prostate, liver).
The book encompasses both large-scale
intergovernmental initiatives as well as recent findings across cancer
stem cells, rational drug design, clinical trials, and chemopreventative
strategies. As a whole, the work articulates and raises the profile of
epigenetics as a therapeutic option in the future management of cancer.
- Concisely summarizes the therapeutic implications of recent, large-scale epigenome studies, including the cancer epigenome atlas
- Discusses
targeted isoform specific versus pan-specific inhibitors, a rational
drug design approach to epigenetics relevant to pharmacoepigenetic
clinical applications
- Covers new findings in the interplay
between cancer stem cells (CSCs) and drug resistance, demonstrating that
epigenetic machinery is a candidate target for the eradication of these
CSCs
